Replimune Group, Inc. (REPL)
After hours:
Replimune Group, Inc.
500 Unicorn Park Drive
Suite 303
Woburn, MA 01801
United States
781 222 9600
https://www.replimune.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 331
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Philip Astley-Sparke F.S.A. | Executive Chairman | 960.52k | N/A | 1971 |
| Ms. Emily Luisa Hill | Chief Financial Officer | 593.05k | N/A | 1980 |
| Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer | 668.69k | N/A | 1967 |
| Dr. Sushil Patel Ph.D. | CEO & Director | 665.05k | N/A | 1971 |
| Dr. Robert Coffin Ph.D. | Founder, Chief Scientist & Director | 785.89k | N/A | 1965 |
| Mr. Andrew Schwendenman | Chief Accounting Officer & Treasurer | N/A | N/A | 1976 |
| Mr. Christopher Sarchi | Chief Commercial Officer | N/A | N/A | 1969 |
| Mr. Paul Bullock | Chief Manufacturing Officer & Framingham Site Head | N/A | N/A | N/A |
Description
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Corporate Governance
Replimune Group, Inc.’s ISS Governance QualityScore as of October 1, 2024 is 8. The pillar scores are Audit: 6; Board: 8; Shareholder Rights: 8; Compensation: 8.
